Identification and Management of Immunotherapy-Related Adverse Events in Oncology

Ozge Gumusa, Laura A. Huppert, Dame Idossa, Hope S. Rugo

Research output: Chapter in Book/Report/Conference proceedingChapter


This chapter provides answers to practice-based questions with case study covering the new principles of diagnosis, classification, staging, treatment, and outcomes in identification and management of immunotherapy-related adverse events in oncology. Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer in the last decade. They include anti-cytotoxic T lymphocyte antigen 4, anti-programmed cell death 1, and anti-programmed cell death 1 ligand 1 antibodies, which are efficacious in multiple cancer types and have demonstrated unprecedented survival in some cases. Immune-related adverse events typically present are usually delayed in onset with prolonged duration. These adverse events most commonly involve the skin, endocrine glands, gastrointestinal system, and liver but can affect almost any organ system. The toxicities due to ICIs require early recognition and optimal management.

Original languageEnglish (US)
Title of host publicationCancer Consult
Subtitle of host publicationExpertise in Clinical Practice, Volume 1: Solid Tumors and Supportive Care
Number of pages13
ISBN (Electronic)9781119823766
ISBN (Print)9781119823735
StatePublished - Jan 1 2023

Bibliographical note

Publisher Copyright:
© 2024 John Wiley & Sons Ltd.


  • Immune checkpoint inhibitors
  • Immunotherapy-related adverse events
  • Oncology
  • Organ system


Dive into the research topics of 'Identification and Management of Immunotherapy-Related Adverse Events in Oncology'. Together they form a unique fingerprint.

Cite this